AbbVie (ABBV) vs. Johnson & Johnson (JNJ)

Company Profile

AbbVie (ABBV) and Johnson & Johnson (JNJ) both fall under the Pharmaceuticals, Biotechnology & Life Sciences industry group, but ABBV is classified in Biotechnology while JNJ is classified in Pharmaceuticals.

Historical Performance

Historical Performance at a Glance

Profitability

Both AbbVie (ABBV) at 95.59% and Johnson & Johnson (JNJ) at 26.26% rank in the top quartile for Return on Equity (TTM) among industry peers, indicating strong returns on shareholders’ equity.

Johnson & Johnson (JNJ) at 21.83% ranks in the top quartile for Net Profit Margin (TTM), ahead of AbbVie (ABBV) at 6.91%, which sits closer to the industry mid-range.

Both AbbVie (ABBV) at 24.65% and Johnson & Johnson (JNJ) at 25.88% rank in the top quartile for Operating Profit Margin (TTM) among industry peers, indicating both companies convert revenue into operating income more strongly than typical competitors.

Profitability at a Glance

Financial Strength

Both AbbVie (ABBV) at 0.67 and Johnson & Johnson (JNJ) at 1.03 run Current Ratio (MRQ) in the tighter-liquidity quartile of industry peers, leaving thinner cushions against current liabilities than typical competitors.

Johnson & Johnson (JNJ) at 0.68 is around its industry mid-range for Debt-to-Equity Ratio (MRQ), while AbbVie (ABBV) at 49.22 sits above its industry benchmark range, pointing to a heavier debt load relative to equity.

Johnson & Johnson (JNJ) at 34.01 ranks in the top quartile for Interest Coverage Ratio (TTM), ahead of AbbVie (ABBV) at 3.46, which sits around the industry mid-range.

Financial Strength at a Glance

Growth

Revenue Growth

Revenue Growth at a Glance

EPS Growth

EPS Growth at a Glance

Dividend

Both AbbVie (ABBV) at 3.11% and Johnson & Johnson (JNJ) at 2.26% report Dividend Yield (TTM) near their industry mid-ranges, so neither company stands out strongly from peers on cash yield relative to share price.

AbbVie (ABBV) reports an unusual Dividend Payout Ratio (TTM) of 275.84% — outside the typical 0–100% range, indicating either negative earnings (negative ratio) or dividends above current-period earnings (above 100%), both signaling sustainability concerns. Meanwhile Johnson & Johnson (JNJ) reports 59.52%, ranking against industry peers normally.

Dividend at a Glance

Valuation

Johnson & Johnson (JNJ) at 26.37 hovers around the typical industry Price-to-Earnings Ratio (TTM), while AbbVie (ABBV) at 88.76 sits above its industry benchmark range — an elevated trailing earnings multiple for ABBV relative to peers.

Both AbbVie (ABBV) at 6.13 and Johnson & Johnson (JNJ) at 5.76 post Price-to-Sales Ratio (TTM) near the typical industry midpoint — neither company stands out strongly from peers on trailing revenue multiple.

Johnson & Johnson (JNJ) at 7.19 hovers around the typical industry Price-to-Book Ratio (MRQ), while AbbVie (ABBV) at 261.01 sits above its industry benchmark range — an elevated book-value multiple for ABBV relative to peers.

Valuation at a Glance